Target intelligence / Profile preview

F18 Fimbriae of Escherichia coli (F18 fimbriae)

Target
F18 fimbriae
Molecular classification
Fimbriae (pilus-like bacterial surface appendage), Bacterial adhesin complex, Surface organelle (extracellular filament structure)
01

Overview

F18 fimbriae are hair-like surface organelles expressed by certain pathogenic strains of Escherichia coli, notably those causing post-weaning diarrhea and edema disease in piglets[1][2]. These fimbriae are assembled via the chaperone-usher pathway and consist of major (FedA), minor (FedE), and tip-adhesin (FedF) subunits, with FedF identified as the key adhesin responsible for binding to glycosphingolipid receptors (specifically ABO blood group type 1 antigens) on the microvilli of porcine small intestinal epithelial cells[1][2][3]. The essential binding domain for adhesion has been mapped to amino acids 60–109 of FedF, with specific residues (His88, Arg117, Lys72, His89) critical for receptor interaction[1][2]. Disruption of this adhesion, either by nanobodies that competitively inhibit the binding site or by antibodies against FedF, blocks bacterial attachment and colonization, highlighting the therapeutic potential of targeting this adhesin[1][3]. The receptor for F18 fimbriae is membrane-associated, requiring specific glycosylation patterns for binding, which explains the host and tissue tropism observed in porcine infections[1][2]. While no drugs are currently approved for clinical use targeting F18 fimbriae, experimental inhibitors (nanobodies, antibodies) have demonstrated efficacy in vitro, establishing F18 fimbriae as a validated antimicrobial target in veterinary medicine[1][3].

Other names
F18 piliF18 adhesin systemFimbrial adhesion system F18F18 fimbria
02

Mechanism of action

Competitive inhibition: Nanobodies such as NbFedF9 bind directly to the carbohydrate-binding site on the FedF adhesin, sterically blocking interaction with host glycan receptors[1]. Conformational disruption: Other nanobodies (e.g., NbFedF6, NbFedF7, NbFedF12) induce conformational changes in the critical D″-E loop of FedF, which is essential for receptor binding, thereby inhibiting adhesion[1]. Antibody-mediated neutralization: Anti-FedF antibodies can inhibit bacterial attachment to host cells, confirming FedF as the functional adhesin[3].

03

Biological functions

Mediates bacterial adhesion to host epithelial cellsEstablishes colonization in host intestineFacilitates initiation of bacterial infectionDetermines host tropism (specificity for piglet enterocytes)
04

Disease associations

Key virulence factor in porcine post-weaning diarrheaAssociated with edema disease in pigletsContributes to infection by enterotoxigenic Escherichia coli (ETEC) and Shiga toxin-producing Escherichia coli (STEC) strains in swine
05

Safety considerations

Potential off-target effects: If used therapeutically, inhibition must be specific to pathogenic E. coli strains without disrupting commensal flora.Development of resistance: Overuse of targeted inhibitors (e.g., nanobodies, antibodies) could select for resistant bacterial strains.Limited host species specificity: F18 fimbriae are primarily pathogenic in pigs, limiting direct human therapeutic relevance.Environmental persistence: F18 fimbriae-producing E. coli can persist in farm environments, complicating infection control.
06

Interacting drugs

NbFedF9

4 more in the full profile.

07

Biomarkers

Expression of the fed gene cluster (particularly fedF) in E. coli isolates from piglets with diarrhea or edema diseasePresence of ABO blood group type 1 determinants (glycosphingolipids) on host enterocytes as the receptor[1]Alpha(1,2)-fucosyltransferase (FUT1) activity in piglet intestinal epithelium, which is essential for receptor presentation and bacterial adhesion[2]

Beyond the preview

Go deeper on F18 Fimbriae of Escherichia coli (F18 fimbriae).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on F18 Fimbriae of Escherichia coli (F18 fimbriae).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call